康缘药业：全资子公司药品增加适应症获批准

Core Viewpoint - Kangyuan Pharmaceutical's wholly-owned subsidiary, Jiangsu Zhongxin Pharmaceutical Co., Ltd., has received a clinical trial approval notice from the National Medical Products Administration for ZX2021 injection to treat metabolic dysfunction-related fatty liver disease [1] Group 1 - The approval signifies a potential expansion of ZX2021's therapeutic applications, which may enhance the company's product portfolio and market competitiveness [1] - This development aligns with the growing focus on metabolic diseases in the pharmaceutical industry, indicating a strategic move by the company to tap into this emerging market [1]